HUSRES Annual Report 2008 Martti Vaara. www.huslab.fi www.intra.hus.fi



Similar documents
HUSRES Annual Report 2010 Martti Vaara

How To Treat Mrsa From A Dead Body

How To Treat Mrsa In Finnish

Helsingin ja Uudenmaan alueen herkkyystilastoja

HUSRES Annual Report 2015

SEA-HLM-415 Distribution: General. Establishment of national laboratory-based surveillance of antimicrobial resistance

Liofilchem - Antibiotic Disk Interpretative Criteria and Quality Control - F Rev.7 /

British Society for Antimicrobial Chemotherapy

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Version 11.1 May 2012

The Five Intravenous Antibiotics You Need to Know

Version 12 May BSAC Methods for Antimicrobial Susceptibility Testing. All enquiries to: Mandy Wootton.

NewYork-Presbyterian Hospital Sites: Columbia University Medical Center Guideline: Medication Use Manual Page 1 of 12

Determination of minimum inhibitory concentrations. Jennifer M. Andrews* Department of Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK

Urinary Tract Infections

ANTIMICROBIAL AGENT CLASSES AND SUBCLASSES

Date: November 30, 2010

The 14th EURL-AR Proficiency Test - enterococci, staphylococci and E. coli Lina Cavaco Susanne Karlsmose Rene S. Hendriksen Frank M.

Received 22 March 2006/Returned for modification 2 May 2006/Accepted 14 September 2006

ANTIBIOTIC RESISTANCE THREATS. in the United States, 2013

Drug Use Review. Edward Cox, M.D. Director Office of Antimicrobial Products

SHEA Position Paper. Vol. 18 No. 4 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY 275

Practice Guidelines. Updated Guideline on Diagnosis and Treatment of Intra-abdominal Infections

Antimicrobial Resistance and Human Health

Beta-lactam antibiotics - Cephalosporins

APPENDIX B: UWHC SURGICAL ANTIMICROBIAL PROPHYLAXIS GUIDELINES

CAP, HAP, VAP, & HCAP

Product Catalogue 2015 Clinical and Industrial Microbiology

Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs

Antibiotic resistance does it matter in paediatric clinical practice? Jette Bangsborg Department of Clinical Microbiology Herlev Hospital

GUIDELINES ON UROLOGICAL INFECTIONS

Optimizing Antimicrobial Susceptibility Test Reporting

GUIDELINES ON UROLOGICAL INFECTIONS

BACTERIOLOGICAL STUDY OF BURNS INFECTION Shareen George 1, K. G. Basavarajappa 2, A. R. Hanumanthappa 3

Antibiotic Guidelines

Antimicrobial Therapy. Otolaryngology Head and Neck Surgery

Oscar E. Guzman, PharmD, BCPS

Intra-abdominal abdominal Infections

BacT/Alert: an Automated Colorimetric Microbial Detection System

Urinary Tract Infection and Asymptomatic Bacteriuria Guidance

SURVEILLANCE REPORT. Antimicrobial resistance surveillance in Europe.

BD Sensi-Disc Susceptibility Test Discs

BITE WOUND INFECTIONS Martin Rodriguez

Appendix M: Guidelines for the Prophylaxis and Management of Intraabdominal, Biliary, and Appendiceal Infections

Management of Extended Spectrum Beta- Lactamase (ESBL) Producing Enterobacteriaceae in health care settings

Received 4 July 2010; returned 10 August 2010; revised 27 September 2010; accepted 30 September 2010

Lecture Outline. Quinolones

bactericidal Gram+ streptococci, enterococci, meningococci, treponema pallidum (syphilis), most anaerobes poor activity against Gram- rods

Antimicrobial Stewardship at the Bedside of Patient Care: Clinical Cases

GUIDELINES ON UROLOGICAL INFECTIONS

Key words: antibiotics, antiseptics, resistance, burns, comlications, microorganisms.

Urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae

The 11 th EURL-AR Proficiency Testing Salmonella and Campylobacter Susanne Karlsmose Lina M. Cavaco Rene S. Hendriksen Frank M.

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors

Global Spread of Carbapenemase- Producing Klebsiella pneumoniae

Klinik für Infektiologie und Institut für Infektionskranhkeiten

The role of MALDI-TOF in Clinical Microbiology, Including the Rapid Identification of Isolates from Positive Blood Cultures

MEDICAL MICROBIOLOGY 603 OR POPULATION HEALTH SCIENCES 603 CLINICAL AND PUBLIC HEALTH MICROBIOLOGY January 18-May 6, 2011

Outpatient Parenteral Antimicrobial Therapy

Original ABSTRACT RESUMEN

IDSA GUIDELINES EXECUTIVE SUMMARY

Nosocomial Antibiotic Resistance in Multiple Gram-Negative Species: Experience at One Hospital with Squeezing the Resistance Balloon at Multiple Sites

GUIDELINES EXECUTIVE SUMMARY

Health PEI: Provincial Antibiotic Advisory Team Skin & Soft Tissue Infection Empiric Treatment Guidelines Prevention

ANTIBIOTICS IN SEPSIS

Use Nisus products to stop wood decay, kill & prevent mold, eliminate odors and control insects.

THERAPY OF ANAEROBIC INFECTIONS LUNG ABSCESS BRAIN ABSCESS

Use Nisus products to stop wood decay, kill & prevent mold, eliminate odors and control insects.

Urinary Tract Infections

Microcyn Technology. Life-Altering Advance in Tissue Care

MERREM I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY

Dosing information in renal impairment

Adult Antimicrobial Guidelines Cork University Hospital

Antimicrobial Resistance Surveillance

CEFADROXIL CAPSULES, USP 500 mg Rx only

Vancomycin. Beta-lactams. Beta-lactams. Vancomycin (Glycopeptide) Rifamycins (rifampin) MID 4

Note. 2.0 Background. 1.0 Introduction RECOMMENDATION

Chemical Name: (±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6- carboxylic acid.

Appropriate Treatment for Children with Upper Respiratory Infection

World Health Organization Department of Communicable Disease Surveillance and Response

Why Do Some Antibiotics Fail?

Central Asian and Eastern European Surveillance of Antimicrobial Resistance

Open Access Article pissn eissn

Disc Diffusion Susceptibility Methods

Guidelines for Antimicrobial Stewardship in Hospitals in Ireland. A Strategy for the Control of Antimicrobial Resistance in Ireland

Transcription:

HUSRES Annual Report 2008 Martti Vaara www.huslab.fi www.intra.hus.fi

The basis of this HUSRES 2008 report is the HUSLAB/Whonet database 2008, which contains susceptibility data on about 180.000 bacteria isolated and studied in 2008 by HUSLAB. The isolates originate from patients in Helsinki University Hospital, other hospitals in Helsinki - Uusimaa region as well as outpatient health centers. HUSRES 2008 report contains data on 31 clinically most important bacterial species/groups. Previous annual reports from 2000 are also located at www.huslab.fi

MRSA, new cases incl. carriers monthly 2001 2008 in Huslab material (Helsinki and Uusimaa District) 2001 2002 2003 2004 2005 2006 2007 2008

Staph. aureus 2008 (%R+I) Pus and blood isolates at seven hospitals (M,T,L,K,N,Kä,Sä) in Helsinki University Central Hospital, from out-patients and from other sources. One isolate per patient (the most resistant). MRSA screenings exluded. Material n Oxa Ery Cli Lev Rif Fus Tob Net Lnz SxT HUCH (7 hosp) 1845 8 9 7 4 0 5 3 0 0 2 Blood isolates 318 4 8 5 4 0 4 2 0 0 1 Jorvi Hospital 587 5 6 5 3 0 4 1 0 0 1 Peijas Hospital 305 7 9 8 6 0 5 7 0 0 0 Helsinki City H 608 4 9 6 4 0 7 3 0 0 2 Outpatients 2405 4 7 5 3 All sources 7930 5 7 6 3 0 6 4 0 0 2

Staph. epidermidis 2008 (%R+I) Pus and blood isolates. HUSLAB material from hospitals in Helsinki and Uusimaa districts. One isolate per patient (the most resistant) Material n Oxa Ery Cli Lev Rif Fus Tob Net Lnz SxT Meilahti hosp. 679 82 66 59 64 22 58 52 8 0 47 Childrens hosp 139 87 70 60 24 9 76 56 10 0 59 All sources 2515 70 60 50 47 18 56 42 6 0 40

Streptococcus pneumoniae 2008 (%R+I) HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the first isolate) All Blood Penicillin - R 1,4 0 Penicillin - I 14 14 Ceftriaxone - R 0,2 0 Ceftriaxone - I 0,1 0 Erythromycin 24 24 Clindamycin 10 6 Doxycycline 11 Sulphamet-Trim. 27 Levofloxacin 0 Moxifloxacin 0 Telithromycin 0 n 949 219

Str. pneumoniae, resistance 2000-2008 Huslab material 30 25 Resistance (% I+R) 20 15 10 5 Penicillin I+R Erythromycin Clindamycin Doxycycline 0 2000 2001 2002 2003 2004 2005 2006 2007 2008

Multiresistance among Str. pneumoniae 2008, multiresistance profiles displayed by > 15 isolates HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the first isolate) % freq n of isolates with this pattern Pen Ery Cli SxT Dox 3,6 34 Pen Ery Cli SxT 1,7 16 Pen Ery SxT 2,4 23 Total number of isolates studied: 949 Multiresistance defined here as non-susceptibility (= R+I) to > three antibacterial agents

Very multiresistant pneumococci (PenR/I, Ery, Cli, SxT, Dox) HUSLAB material 2001-2008 40 35 30 number of patients 25 20 15 10 5 0 2001 2002 2003 2004 2005 2006 2007 2008

Beta-hemolytic streptococci 2008 (%R+I) HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). S. pyogenes S. agalact. Group G Penicillin 0 0 0 Cephalosp. I gen 0 0 0 Erythromycin 3 11 12 Clindamycin 2 10 10 n 9679 3992 3727 Group G: S. dysgalactiae spp. equisimilis group G strains

Streptococcus viridans group, blood isolates 2008 HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). Penicillin -I 14 Penicillin -R 2 Ceftriaxone -I 0 Ceftriaxone -R 0 Erythromycin I+R 28 Clindamycin 8 Gentamycin -high res. 0 Vancomycin 0 n = 155

Str. anginosus [milleri] group 2008 (%R+I) Pus and blood isolates, HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). Penicillin 0 Cephalospor. I gen. 0 Erythromycin 9 Clindamycin 8 Vancomycin 0 n = 626

Enterococci 2008 %R+I (pus & blood); %R (urine). HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the most resistant). E. faecalis E. faecium pus blood urine pus blood urine Ampicillin 0 0 0 95 90 98 Imipenem 0 0 94 90 Linezolide-I 0 0 0 0 Linezolide-R 0 0 0 0 Vancomycin 0 0 0 1 0 0 Gentam. (hi) 14 12 Levofloxacin 31 82 Moxiflox MIC>8 31 82 Norfloxacin 26 98 Nitrofurantoin 1 88 SuTri 18 92 n 1586 96 4389 579 59 1230

Pseudomonas aeruginosa 2008 (%R+I) Pus and blood isolates. One isolate per patient (the most resistant isolate). HUSLAB material from selected hospitals in Helsinki and Uusimaa Districts. Pus isolates from n Ctaz Mero Pi-Tz Tob Ami Cip Meilahti 242 9 13 9 6 5 23 Töölö 162 5 10 9 8 5 28 Helsinki City hospitals 217 1 6 4 5 3 25 Jorvi Hospital 144 2 9 6 5 3 16 Peijas Hospital 63 6 5 11 3 2 17 Childrens 39 5 8 0 3 3 3 Uusimaa regional hospitals 183 3 7 4 3 1 14 Outpat. in Health Cntrs 630 2 4 5 4 1 16

Ps. aeruginosa in Meilahti hospital, frequency of isolates resistant to > four of the six commonly available agents a) a) Ctaz, Mero, Pi-Tz, Cip, Tob, Ami, Resistance defined here as nonsusceptibility (= R+I), Huslab material. One isolate per patient Frequency (%) of isolates resistant to 2003 2004 2005 2006 2007 2008 all six (= panresistant) 3.0 1 0,4 0 0,7 1,2 five 4,2 3,4 1,9 0,8 1 0,4 four 11,1 6,5 5,7 2,4 1,9 2,2 total number of isolates studied 334 294 265 376 419 494

Ps. aeruginosa and Acinetobacter at HUS, the number of extremely multiresistant isolates The total number of isolates (one per each patient) of Pseudomonas aeruginosa (PSE) and Acinetobacter (ACI) that are extremely resistant (in Pseudomonas, all six to five clinically used key antibiotics inert and in Acinetobacter (ACI, all seven to six clinically used key antibiotics inert). 80 70 60 50 40 30 ACI PSE 20 10 0 2001 2002 2003 2004 2005 2006 2007 2008

Acinetobacter spp. 2008 (%R+I) Pus and blood isolates from selected hospitals in Helsinki University Hospital. One isolate per patient (the most resistant) Hospital n Ctaz Mero Pi-Tz Tob Levo SuTri Meilahti 63 7 3 8 3 6 19 Töölö 76 13 1 7 1 5 9 Other sources 114 5 0 8 2 2 4

Acinetobacter spp. in Töölö hospital 2002-2008 Resistance (%R+I) Pus and blood isolates. One isolate per patient (the most resistant) n Ctaz Mero Pi-Tz Tob Cip SuTri 2002 130 25 15 26 21 23 27 2003 112 17 10 20 14 13 17 2004 101 12 2 8 13 13 16 2005 153 33 25 29 33 35 33 2006 90 21 16 17 18 17 23 2007 73 18 8 10 19 14 12 2008 76 13 1 7 1 5 9

Stenotrophomonas maltophilia 2008 (%R+I) Pus and blood isolates. One isolate per patient (the most resistant isolate). HUSLAB material from hospitals in Helsinki and Uusimaa Districts. Hospital n SxT Mino Tige Levo Tic-cla MIC > 2 Meilahti 111 6 4 29 49 Töölö 52 2 2 23 38 Childrens 12 8 0 9 50 Other sources 224 7 0 17 43 All sources 399 6 0 69 17 43 All S. maltophilia strains display natural resistance (R) to aminoglycosides, carbapenems and piperacillin-tazobactam and are non-susceptible (R or I) to ceftazidime

Enterobacteriaceae 2008 (%R+I) Pus and blood isolates at seven hospitals (M,T,L,K,N,Kä,Sä) in Helsinki University Central Hospital. One isolate per patient (the most resistant) n Cfur Ctax Pi-Tz Tob Levo Mero E. coli 979 11 8 8* 8 13 0 Kl. pneumoniae 187 13 5 5* 3 5 0 Kl. oxytoca 147 12 3 3* 0 1 0 Proteus mirabilis 86 0 0 0 2 0 0 Ent. cloacae 336 44 33 33** 4 3 1 Enterobact. spp. 56 42 26 26** 0 0 2 Citrob. spp. 140 33 27 27** 1 3 0 Serratia marc. 124 96 8 8** 6 6 0 Proteus vulgaris 41 88 0 0 0 0 0 Morganella morg 51 88 8 8** 2 4 0 Total 2176 27 13 13 5 7 0,1 (Total 2007) 2693 26 11 11 6 8 0,1 (Total 2006) 2303 24 10 10 5 8 0 (Total 2005) 2312 25 10 10 5 8 0,2 *: all ESBL strains reported here as nonsusceptible **: all cefotaxime-resistant strains (mainly ampc strains) reported as nonsusceptible

ESBL 2008 (% frequency and number of cases) at different locations HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the most resistant) E. coli K. pneumoniae Material % no. of % no. of patients w. ESBL patients w. ESBL HUCH, Helsinki (7 hospitals) 5 162 2 13 Helsinki City hospitals 5 202 1 6 Helsinki City outpatients 3 236 3 31 Hyvinkää Regional Hospital 2 26 2 4 Jorvi Hospital 3 37 2 3 Peijas Hospital 3 26 1 2 All sources 3 806 1 41

Bacteremias caused by E. coli ESBL, HUSLAB material 2001-2008 30 25 20 Cases 15 10 5 0 2001 2002 2003 2004 2005 2006 2007 2008

Frequency of E. coli ESBL at HUCH/Helsinki 2000-2008 9 8 7 6 One strain per patient % ESBL 5 4 3 2 1 0 Pus & B Urine 2000 2001 2002 2003 2004 2005 2006 2007 2008 Martti Vaara March 3, 2009

E. coli ESBL in Huslab material 2004 2008, Number of new cases by age categories 300 Number of new cases 250 200 150 100 50 2004 2005 2006 2007 2008 0 0-20 21-40 41-60 61-80 81-100 Age group Martti Vaara, March 3, 2009

ESBL strains, resistance to non-betalactams and carbapenems 2007-2008 % R+I in blood, pus, and urine isolates. HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the most resistant isolate) Antibiotic E. coli K. pneum. Ciprofloxacin 84 64 Levofloxacin 84 64 Norfloxacin 79 61 Tobramycin 60 56 Sulphatrimetoprim 47 71 Trimetoprim 50 77 Nitrofurantoin 5 64 Meropenem 0,2 0 Imipenem 0 0 Ertapenem 0,8 17 Tigecycline 4 (n = 56 ) 29 (n = 7 ) n 1418 83

Enterobacteriaceae, urine isolates 2008 (%R) HUSLAB material from Helsinki and Uusimaa districts. One isolate per patient (the most resistant) E. coli Kl. pneum. P. mirabilis Other Nitrofurantoin 1 13 99 29 Mecillinam 4 4 3 14 Cephalexin 10 7 2 50 Norfloxacin 8 2 2 3 Sulphameth-trimet. 23 20 23 19 Trimetoprim 22 21 40 21 n 22885 2679 910 2069

H. influenzae & M. catarrhalis 2008 (%R+I) HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). H. influenzae M. catarrh. Ampicillin 21 97 Amoxycill-clavul. 3 0 Cefuroxime 1 0 Doxycycline 2 0 Ciprofloxacin 0 0 Sulphameth-trim. 20 3 Azithromycin 0 1 n 708 344

Neisseria meningitidis 2006-2008 (%R+I) HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). Penicillin-I 0 Penicillin-R 0 Cephtriaxone 0 Meropenem 0 Ciprofloxacin 0 Chloramphenicol 0 n 61

Neisseria gonorrhoeae 2007-2008 (%R+I) HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). n = 119 Ciprofloxacin 67 Ceftriaxone 0 Azithromycin 1

Bacteroides fragilis group 2008 (%R+I) HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). n = 1120 Metronidazole 0 Piperacillin-tazobactam 1 Imipenem 1 Clindamycin 54 Doxycycline 8 Penicillin G 100

Prevotella spp. 2008 (% I+R) Pus isolates, HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). Penicillin 58 Piperacillin-Taz. 1 Doxycyclin 9 Metronidazole 0 Clindamycin 17 n = 592

Salmonella 2007-2008, susceptibility to ciprofloxacin HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). n = 917, breakpoints according to CLSI S I R

Salmonella typhi 2004-2008, susceptibility to ciprofloxacin HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). n = 11, breakpoints according to CLSI S I R

Campylobacter 2008, resistance (%R+I) and multiresistance profiles HUSLAB material from Helsinki and Uusimaa Districts. One isolate per patient (the first isolate). C. jejuni C. coli Ciprofloxacin 53 55 Erythromycin 3 3 Cip + Ery 1 7 Cip + Ery + Dox 0 5 n 694 152